Health and Healthcare

Aeterna Zentaris Rises on Finalized Marketing Agreement

Thinkstock

Aeterna Zentaris Inc. (NASDAQ: AEZS) was leading the bulls in Tuesday’s regular trading session. The company announced that it has finalized of a co-marketing agreement with Armune BioScience that will allow it to promote Armune’s Apifiny, the only cancer specific, non-PSA blood test for the detection of prostate cancer.

Under the co-marketing agreement, Aeterna Zentaris will promote Apifiny to designated medical professionals in its U.S. territories and will receive a commission for each test performed resulting from its targeted promotion.

Apifiny is a simple, non-PSA based measure for patients and their clinicians to aid in assessment of prostate cancer risk. It enhances the focus on the oncology marketplace in general and on the diagnosis, monitoring and treatment of prostate cancer in particular. Also recently it was reported that Zoptrex demonstrated potential as a treatment for certain types of prostate cancer in an investigator-sponsored Phase 2 trial.

David A. Dodd, chairman, president and CEO of Aeterna Zentaris, said:

Promoting Apifiny will give our sales force experience in the oncology market, which will serve us well as we move toward the commercialization of Zoptrex, if it is approved by the FDA. We are also looking forward to developing a much more in-depth relationship with Armune in connection with the evaluation of Zoptrex for prostate cancer and perhaps other indications.

David A. Esposito, president and CEO of Armune BioScience, added:

We are very excited to begin our partnership with Aeterna Zentaris through this initial agreement. The experience and expertise of the commercial and research teams at Aeterna Zentaris will be extremely helpful to Armune as we accelerate the growth of APIFINY and develop our autoantibody technology across major areas of unmet need in cancer. In less than eight months on the market, APIFINY has been ordered over 2,500 times as clinicians move beyond PSA-based testing to assess prostate cancer risk. Aeterna Zentaris will help us achieve the full potential of this opportunity.

Shares of Aeterna Zentaris were trading up 8.7% at $10.54 Tuesday, with a consensus analyst price target of $52.50 and a 52-week trading range of $3.19 to $89.00.

ALSO READ: Huge PowerShares ETF Rebalance Means Massive Buying for 4 Biotech Stocks

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

 

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.